• 1. An ionic liquid promoted microwave-hydrothermal route towards highly photoluminescent carbon dots for sensitive and selective detection of iron(iii)?
  Ruili Liu,Mengping Gao,Jing Zhang,Zhilian Li,Jinyang Chen,Ping Liu,Dongqing Wu RSC Adv., 2015,5, 24205-24209
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 4. Alt-proteins: A promising future
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Oxadiazoles 1,2,4-oxadiazoles

Recent Advances in the Study of 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine (CAS: 932742-86-4)

The compound 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine (CAS: 932742-86-4) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential.

Recent studies have highlighted the versatility of 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine as a key intermediate in the synthesis of novel bioactive molecules. The oxadiazole ring, a prominent feature of this compound, is known for its stability and ability to participate in hydrogen bonding, making it a valuable scaffold in medicinal chemistry. Researchers have successfully utilized this compound to develop inhibitors targeting various enzymes, including kinases and proteases, which are implicated in numerous diseases.

One notable study published in the Journal of Medicinal Chemistry demonstrated the efficacy of derivatives of 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine in modulating the activity of protein kinases involved in cancer progression. The study employed a combination of molecular docking and in vitro assays to identify potent inhibitors with high selectivity and low cytotoxicity. These findings suggest that this compound could serve as a promising lead for the development of targeted cancer therapies.

In addition to its applications in oncology, 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine has also been investigated for its potential in treating neurological disorders. A recent preprint on bioRxiv reported that derivatives of this compound exhibited neuroprotective effects in models of Alzheimer's disease. The researchers attributed these effects to the compound's ability to inhibit amyloid-beta aggregation and reduce oxidative stress in neuronal cells.

Despite these promising results, challenges remain in optimizing the pharmacokinetic properties of 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine derivatives. Issues such as poor solubility and metabolic instability have been identified as potential barriers to clinical translation. Ongoing research is focused on structural modifications to enhance the drug-like properties of these compounds while retaining their biological activity.

In conclusion, 4-(5-Methyl-1,2,4-oxadiazol-3-yl)benzenemethanamine (CAS: 932742-86-4) represents a valuable scaffold in medicinal chemistry with diverse therapeutic potential. Continued research efforts are expected to yield novel derivatives with improved efficacy and safety profiles, paving the way for their eventual clinical application.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)